Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STACCATO I/II: Antiviral Control of CMV Anterior Uveitis
NCT07513623Phase 2Not yet recruiting
- Sponsor
- University of California, San Francisco
- Start
- Nov 2026
- Primary completion
- Dec 2031
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
A Phase 2 trial of valganciclovir, ganciclovir in Cytomegalovirus anterior uveitis, sponsored by University of California, San Francisco. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
valganciclovirganciclovir
03
Conditions
Cytomegalovirus anterior uveitis
Beyond the preview
Go deeper on NCT07513623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513623.